Drug Database
Back to search

Poland· PL-100371259

Remurel

A glatiramer acetate product containing glatirameri acetas, registered in Poland by Zentiva, k.s.. The same ATC class is registered in 14 of our 19 countries.

ATC L03AX13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedRemurelATCL03AX13REGISTER NO.PL-100371259PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glatirameri acetasAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glatiramer acetate is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AX13 (glatiramer acetate), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search glatiramer acetate products by name

Glatiramer acetate · ATC L03AX13

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Glatirameri acetas
Manufacturer
Zentiva, k.s.
Country
Poland (PL)
ATC code
L03AX13
ATC class
Glatiramer acetate
Defined daily dose
20 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991353919
  • gtin
    05909991353926
  • gtin
    05909991353933

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for glatiramer acetate.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check glatiramer acetate against other medicinesHow interaction checks work

Glatiramer acetate · interactions on record

2 records

  • 2 severe

Most severe, free to view

  • NatalizumabL04AA23severe
  • NatalizumabL04AG03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glatiramer acetate in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glatiramer acetate products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • France · Copaxone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d739a561-5425-42fb-bcfc-07b3a37ee0f4
GET /v1/drugs/d739a561-5425-42fb-bcfc-07b3a37ee0f4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "40 mg/ml",
  "packaging": "05909991353919 ¦ Rp ¦ 125449\n3 amp.-strzyk. 1 ml\n05909991353926 ¦ Rp ¦ 125450\n12 amp.-strzyk. 1 ml\n05909991353933 ¦ Rp ¦ 125451\n36 amp.-strzyk. 1 ml",
  "substance": "Glatirameri acetas 40 mg/ml",
  "common_name": "Glatirameri acetas",
  "pl_product_id": "100371259",
  "pozwolenie_nr": "24402",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about glatiramer acetate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console